SEC Form 4 · accession 0001179110-18-014316
Axogen, Inc. · AXGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Erick Wayne DeVinney
Officer — VP, Clinical&Translational Sc
Period of report
Dec 27, 2018
Accepted (ET)
Dec 31, 2018 · 4:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000805928
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to purchase)F1 | $19.17 | Dec 27, 2018 | A | 11,900 | A | — | Dec 27, 2028 | Common Stock | 11,900 | 11,900 | D |
| Restricted Stock UnitsF2,F3 | — | Dec 27, 2018 | A | 3,000 | A | — | — | Common Stock | 3,000 | 3,000 | D |
Explanation of responses
- F1All shares of AxoGen, Inc. common stock underlying the employee stock option will be fully vested on December 27, 2022 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.
- F2Each restricted stock unit represents a contingent right to receive one share of AxoGen, Inc. common stock.
- F3All shares of AxoGen Inc. common stock underlying the restricted stock Units will be fully vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.